---
title: "SEELQ.US (SEELQ.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/SEELQ.US/news.md"
symbol: "SEELQ.US"
name: "SEELQ.US"
parent: "https://longbridge.com/en/quote/SEELQ.US.md"
datetime: "2026-05-21T05:29:08.526Z"
locales:
  - [en](https://longbridge.com/en/quote/SEELQ.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/SEELQ.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/SEELQ.US/news.md)
---

# SEELQ.US (SEELQ.US) — Related News

### [Psychiatry Drug Maker Seaport Therapeutics Jumps 10% in U.S. IPO Debut](https://longbridge.com/en/news/284946947.md)
*2026-05-01T23:09:58.000Z*
> Boston-based biotech company Seaport Therapeutics Inc. (SPTX) raised nearly $255 million in its initial public offering 

### [The IPO Buzz: Seaport Therapeutics Increases IPO’s Size & Prices it at $18 – Top of Range](https://longbridge.com/en/news/284896142.md)
*2026-05-01T12:00:58.000Z*
> Seaport Therapeutics (SPTX), a Boston-based biotech, has increased its IPO size to 14.16 million shares, priced at $18.0

### [Seaport Therapeutics Prices Upsized IPO Of 14.16 Mln Shares At $18 Each](https://longbridge.com/en/news/284868671.md)
*2026-05-01T05:54:00.000Z*
> Seaport Therapeutics, Inc. has priced its upsized IPO of 14.16 million shares at $18 each, raising approximately $254.9 

### [Avalyn Announces Pricing of Upsized Initial Public Offering](https://longbridge.com/en/news/284671903.md)
*2026-04-30T01:00:00.000Z*
> On April 29, 2026, Avalyn Pharma Inc. announced the pricing of its upsized initial public offering, consisting of 16,666

### [Seaport and Hemab target $180m IPOs as biotech listings accumulate](https://longbridge.com/en/news/284375788.md)
*2026-04-28T10:22:38.000Z*
> A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings.

### [Neuropsychiatric drug developer SeaportIPO prices at $16-18 per share, aiming to raise $201 million](https://longbridge.com/en/news/284339355.md)
*2026-04-28T09:02:33.000Z*
> Biotechnology company Seaport Therapeutics, focused on developing therapies for neuropsychiatric disorders, announced it